FIGURE 9.

Blockade of IL-6 or STAT3 does not affect cell viability in human primary hepatocytes treated with doxorubicin. A, human primary hepatocytes were treated with 500 ng/ml of anti-IL-6 antibody or 0.5 μm LLL12 for 2 h and 24 h, respectively. After 24 h, cell viability was measured. Non-treated cells (NT) were used as control. The data represented three independent results. B, human primary hepatocytes were pretreated with 500 ng/ml of anti-IL-6 antibody or 0.5 μm LLL12 for 2 h. After the pretreatment, LLL12 was discarded and fresh medium with different concentrations of doxorubicin was added. After 24 h, cell viability was measured. The data represented three independent results.